Prospective strategies to enforce selectively cell death in cancer cells
MV Blagosklonny - Oncogene, 2004 - nature.com
Although induction of apoptosis (cell death mediated by caspases) determines response to
cancer therapy, this approach is limited by lack of selectivity in available apoptosis-inducing …
cancer therapy, this approach is limited by lack of selectivity in available apoptosis-inducing …
Therapeutic potential of natural compounds that regulate the activity of protein kinase C
CA Carter, CJM Kane - Current medicinal chemistry, 2004 - ingentaconnect.com
Protein kinase C (PKC) is a family of serine/threonine kinases that regulates a variety of cell
functions including proliferation, gene expression, cell cycle, differentiation, cytoskeletal …
functions including proliferation, gene expression, cell cycle, differentiation, cytoskeletal …
Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids
BR Haugen, LL Larson, U Pugazhenthi… - The Journal of …, 2004 - academic.oup.com
Therapy for patients with advanced thyroid carcinoma is limited. Clinical and in vitro studies
suggest that some patients with advanced thyroid cancer may respond to therapy with …
suggest that some patients with advanced thyroid cancer may respond to therapy with …
Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma
SM Coelho, R Corbo, A Buescu, DP Carvalho… - Journal of …, 2004 - Springer
De-differentiated thyroid carcinoma is characterized by loss of thyroid-specific functions and
properties. The therapeutic options for this type of thyroid cancer are limited and generally …
properties. The therapeutic options for this type of thyroid cancer are limited and generally …
A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer
SC Short, A Suovuori, G Cook, G Vivian, C Harmer - Clinical Oncology, 2004 - Elsevier
AIMS: Radio-iodine is effective in treating metastatic differentiated thyroid cancers. In 20% of
cases, however, these tumours fail to take up radio-iodine, and treatment options are then …
cases, however, these tumours fail to take up radio-iodine, and treatment options are then …
Effect of peroxisome proliferator-activated receptor γ agonist, rosiglitazone, on dedifferentiated thyroid cancers
JC Philips, C Petite, JP Willi, F Buchegger… - Nuclear Medicine …, 2004 - journals.lww.com
Results Although thyroglobulin levels increased in four of the five patients after 3 months of
treatment with rosiglitazone, the 131 I scan remained negative in four patients and became …
treatment with rosiglitazone, the 131 I scan remained negative in four patients and became …
Decreased expression of retinoid X receptor isoforms in human thyroid carcinomas
Y Takiyama, N Miyokawa, A Sugawara… - The Journal of …, 2004 - academic.oup.com
Retinoid X receptors (RXRs) are ligand-inducible transcription factors that belong to the
superfamily of nuclear hormone receptors. Because RXRs heterodimerize with thyroid …
superfamily of nuclear hormone receptors. Because RXRs heterodimerize with thyroid …
Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy
MS Haq, RV McCready, CL Harmer - Nuclear Medicine …, 2004 - journals.lww.com
Objectives This was a retrospective study to assess the efficacy and morbidity of high activity
131 I therapy in patients with advanced differentiated thyroid carcinoma. Methods From …
131 I therapy in patients with advanced differentiated thyroid carcinoma. Methods From …
Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses
C Schmutzler, C Hoang-Vu, B Rüger… - European Journal of …, 2004 - academic.oup.com
Objective Disturbed expression of retinoic acid (RA) receptors (RAR/RXR) contributes to the
pathogenesis and tumor progression of epithelial carcinomas. Design To examine whether …
pathogenesis and tumor progression of epithelial carcinomas. Design To examine whether …
The sodium-iodide symporter
CH Baker, JC Morris - Current drug targets-immune, endocrine …, 2004 - ingentaconnect.com
The sodium-iodide symporter (NIS) is an intrinsic plasma membrane protein that mediates
active transport of iodide in the thyroid gland and several other extra-thyroidal tissues. This …
active transport of iodide in the thyroid gland and several other extra-thyroidal tissues. This …